Drug Approvals
Page 1 • 12 itemsTrack global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.
Orchard Therapeutics OTL-201: Innovation Passport for MPS-IIIA
Orchard Therapeutics has secured an Innovation Passport designation from the MHRA for its investigational gene therapy, OTL-201, targeting MPS-IIIA. This marks a significant step in accelerating development and access for patients with Sanfilippo syndrome type A.
MHRA Post-Brexit Drug Approval: What You Need to Know
Learn about the MHRA's new drug approval process post-Brexit and its impact on the availability of essential medications like Ozempic for diabetes.
MHRA Drug Approval Divergence: UK vs EU Market Access & Investment Impact
This article delves into the differences in MHRA drug approval processes for [Drug Name] in [Indication], highlighting their effects on market access and investment strategies in the UK and EU.
Auvelity FDA Approval: A New MDD Treatment Option
The FDA has approved Auvelity, a novel oral therapy from Axsome Therapeutics, for the treatment of major depressive disorder (MDD). This marks a significant advancement in MDD treatment options.
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.
MHRA post-Brexit drug approval: Market Impact on UK-EU Pharma Firms
This article examines how the MHRA's post-Brexit drug approval process affects UK-EU pharmaceutical firms, highlighting the implications for drugs like XYZ for chronic pain.
EU HTA Regulation Impact: Effects on Rare Disease Drug Approvals & Market Access
This article examines how the EU HTA Regulation influences the approval and market access of rare disease drugs, focusing on Zolgensma for spinal muscular atrophy.
EU HTA Regulation Impact: First Year Review on Drug Approval Timelines
This article reviews the first year of the EU HTA Regulation, analyzing its effects on drug approval timelines for therapies such as XYZ for cancer.
EMA Conditional Marketing Authorization: Oncology Approvals & EU Patient Access
This article delves into the EMA's Conditional Marketing Authorization process, focusing on oncology drug approvals and their impact on patient access in the EU.
EMA Conditional Marketing Authorization: Impact on Oncology Patient Access in EU
This article examines the impact of EMA Conditional Marketing Authorization on improving access to innovative oncology drugs, such as XYZ, for patients in the EU.
EMA Conditional Approval Pathway: Case Study on Repotrectinib Oncology Drug
This article delves into the EMA Conditional Approval Pathway, highlighting the case study of Repotrectinib for treating ROS1-positive oncology patients.
![EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing](/uploads/articles/ema-biosimilar-approvals-specific-drug-market-analysis-2024.webp)
EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing
Discover how the 2024 EMA biosimilar approvals will affect the market dynamics and pricing strategies for [Specific Drug] used in treating [Indication].